Kairos Pharma is a clinical-stage biopharmaceutical company focused on developing cancer therapeutics, with no approved products and no product revenue. Kairos's pipeline centers on two core problems in oncology: tumor resistance to existing therapies and immune suppression by cancer cells. Its most advanced asset, ENV 105 (carotuximab), is an antibody targeting endoglin (CD105), a protein upregulated when tumors develop resistance to standard treatments. Rather than replacing existing drugs, ENV 105 is designed to re-sensitize tumors to therapies they've already become resistant to. ENV 105 is currently in a Phase 2 trial in castrate-resistant prostate cancer (combined with apalutamide) and a Phase 1 trial in EGFR-mutant non-small cell lung cancer (combined with osimertinib), both conducted at third-party academic medical centers. Kairos's second most advanced asset, KROS 201, is a patient-specific T cell therapy targeting glioblastoma, with a Phase 1 trial planned. The company has five additional earlier-stage candidates targeting immune checkpoints, tumor growth pathways, and chemotherapy resistance. Kairos operates virtually with one full-time employee and three part-time executives. It licenses its intellectual property from Cedars-Sinai and has a license and supply agreement with Tracon Pharmaceuticals for ENV 105. Kairos funds itself through equity issuances, including a 2024 IPO, a 2025 PIPE, an equity line of credit, and an ATM offering. Its long-term strategy is to outlicense or partner drug candidates with larger pharmaceutical companies, or ultimately commercialize approved products.